Hyaluronic Acid-enriched Transfer Medium in Single Blastocyst Transfer
Use of Hyaluronic Acid-enriched Transfer Medium in Women Undergoing Single Blastocyst Transfer : a Multicenter, Randomized Controlled Trial
Northwest Women's and Children's Hospital, Xi'an, Shaanxi
858 participants
Sep 13, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to compare the live birth rates of high concentration of Hyaluronic Acid (0.5 mg/ml) transfer medium (EmbryoGlue®) to those containing low Hyaluronic Acid concentrations (0.125 mg/ml) (G2 medium) in women undergoing single fresh and frozen blastocyst transfer.
Eligibility
Inclusion Criteria4
- All cycles with single blastocyst transfer will be considered eligible
- Both fresh and cryopreserved embryo transfer cycles utilizing autologous oocytes
- No age restriction will be applied
- Informed consent was signed
Exclusion Criteria3
- Uterine anatomic anomalies
- Women with untreated hydrosalpines
- Once couples have been enrolled in the trial, subsequent cycles will not be incorporated.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Hyaluronic Acid(EmbryoGlue®)
Hyaluronic Acid (G2 medium)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06492785